10,00	09-19	02		of 1632/b
Under We Paperwork Reduction	n Act of 1995, no persons are required to r	U.S. Patent and Trader	oved for use through 10/31/2002 mark Office: U.S. DEPARTMENT	COECOMMERCE / Y./
M S	no posedno die reguliee e r	Application Number	09/693,75	
TRA	NSMITTAL	Filing Date	10/20/200	i
	FORM	First Named Inventor	N. Berinstei	RECEIVE
	ll correspondence after initial filing)	Group Art Unit		SEP 2 3 2002
U.S. Express Mail E	L667440178US	Examiner Name	I A AJ C WPLLA	,
Total Number o	f Pages in This Submission	Attorney Docket Number	er 13115	TECH CENTER 1600/2
	ENCL	OSURES (check	all that apply)	
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/dec Extension of Time Re Express Abandonme Information Disclosu Certified Copy of Pric Document(s) Response to Missing Incomplete Application Response to Minder 37 CFR	claration(s) Petition Provision Pro	ng-related Papers to Convert to a constant population of Attorney, Revocation of Correspondence	After Allowance Comto Group Appeal Communication of Appeals and Inter Appeal Communication (Appeal Notice, Brief, Reply Proprietary Informat Status Letter Other Enclose identify below 1. Respirate to Motion 2. Paper Copy I na. 3. Computer - trade new slayeres 4. Postrard	ion to Board ferences ion to Group y Brief)
· -	SIGNATURE OF APPLI	CANT, ATTORNEY, OR	AGENT	
Firm <i>or</i> Individual name	Patrick J. Halloran			DA
Signature	Dg Bur			
Date	9/18/02			
		ATE OF MAILING		
I hereby certify that this corre mail in an envelope addresse	espondence is being deposited with the ded to: Commissioner for Patents, Was	ne United States Postal Serv shington, DC 20231 on this d	ice with sufficient postage as ate:	first class
Typed or printed name				
Signature	·	Pot		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

EE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) //0.00

Cor	nplete if Known		
Application Number	09/693,754		
Filing Date	10/20/2000	DEOE	
First Named Inventor	N. Beinstein	RECEIV	FD
Examiner Name	A.M.S. Welbe	SEP 2 3 2	102
Group Art Unit	1632		JUZ
Attorney Docket No.	13115 TF(CH CENTER 16	nn/2ar
		Private IV	VV/ L U

METHOD OF PAYMENT	FEE CALCULATION (continued)				
1. The Commissioner is hereby authorized to charge indicated fees and credit any overnayments to:	3. ADDITIONAL FEES				
Deposit	Large Small				
Account Number 50-0244	Entity Entity Fee	Fee Paid			
Deposit	Code (\$) Code (\$)				
Account Aventis Pasdeur	105 130 205 65 Surcharge - late filing fee or oath				
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet				
Applicant claims small entity status.	139 130 139 130 Non-English specification				
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination				
2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action				
Check Credit card Money Other	113 1,840* 113 1,840* Requesting publication of SIR after				
FEE CALCULATION	Examiner action	110.00			
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month	110.00			
Large Entity Small Entity	116 400 216 200 Extension for reply within second month				
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 920 217 460 Extension for reply within third month				
101 740 201 370 Utility filing fee	118 1,440 218 720 Extension for reply within fourth month				
106 330 206 165 Design filing fee	128 1,960 228 980 Extension for reply within fifth month				
107 510 207 255 Plant filing fee	119 320 219 160 Notice of Appeal				
108 740 208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal				
114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing				
01177741 (4) (4)	138 1,510 138 1,510 Petition to institute a public use proceeding				
SUBTOTAL (1) (\$)	140 110 240 55 Petition to revive - unavoidable				
2. EXTRA CLAIM FEES Fee from	141 1,280 241 640 Petition to revive - unintentional				
Extra Claims below Fee Paid	142 1,280 242 640 Utility issue fee (or reissue)				
Total Claims20** = X =	143 460 243 230 Design issue fee				
Claims Line - 3 - Land ^ Land = 1	144 620 244 310 Plant issue fee				
Multiple Dependent	122 130 122 130 Petitions to the Commissioner				
Laura Fallin D. H. F. du	123 50 123 50 Processing fee under 37 CFR 1.17(q)				
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt				
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)				
102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection	1			
104 280 204 140 Multiple dependent claim, if not paid	(37 CFR § 1.129(a))				
109 84 209 42 ** Reissue independent claims over original patent	149 740 249 370 For each additional invention to be examined (37 CFR § 1.129(b))				
110 18 210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)				
and over original patent	169 900 169 900 Request for expedited examination of a design application				
SUBTOTAL (2) (\$)	Other fee (specify)				
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) //	0.00			

SUBMITTED BY	SUBMITTED BY Complete (if applicable)			f applicable)	
Name (Print/Type)	Patrick J Hallorun	Registration No. (Attorney/Agent)	41,053	Telephone	570 839 5446
Signature	80 Hall			Date	September 18, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

146 20-45-6 27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Docket No. 13115)

RECEIVED

In The Application of:

SEP 2 3 2002

Barber, et al.

TECH CENTER 1600/2900

Serial No.: 09/693,754

Examiner: Dr. A.M.S. Webbe

Filed: October 20, 2000

) Art Unit: 1632

For:

METHOD OF INDUCING AND/OR

ENHANCING AN IMMUNE RESPONSE

TO A TUMOR ANTIGEN

Assistant Commissioner For Patents BOX SEQUENCE Washington, DC 20231 U.S. Express Mail EL667440178US

RESPONSE TO NOTICE TO COMPLY DATED JULY 24, 2002

Sir / Madam,

This is a response to the Notice to Comply dated July 24, 2002. Attached herewith are: 1) transmittal form; 2) fee transmittal form; 3) petition for a one-month extension of time; 4) paper copy of the new sequence listing; 5) computer-readable copy of the new sequence listing; and, 6) postcard. Applicants do not believe any additional petitions or fees are due. However, if this is in error, the undersigned hereby makes any such petitions and authorizes the Commissioner to deduct any additional fees or credit any overpayments to Deposit Account No. 50-0244.

Please amend the instant specification by inserting the new Sequence Listing as pages 43-71 and renumbering the remaining pages accordingly. The Sequence Listing includes nucleotide and amino acid sequences that can be found in the application as originally filed. Accordingly, no new matter has been introduced into the application as a result of the present amendment. The undersigned representative hereby declares that the content of the paper and computer readable copies of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are identical in content. The 3.5" diskette contains a computer-readable text file of the sequence listing named "USAppl 09_693754.ST25.txt". Consideration and entry of this Statement and attachments is respectfully requested.

Respectfully submitted,

AVENTIS PASTEUR

Date: September 18, 2002

Patrick I Halloran Reg. No. 41,053

Aventis Pasteur Discovery Drive Swiftwater, PA 18370 Tel: 570-839-5446

Fax: 570-895-2702

Application No.: 09/693,754

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
X	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
П	7. Other:
Αp	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entrinto the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216
	r CRF Submission Help, call (703) 308-4212
Fo	r Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE